Innoviva, Inc. - 8-K Filing
Innoviva reports Q3 2026 net loss of $73.9 million due to $139.5 million decline in investment fair value despite 45% YoY growth in U.S. specialty therapeutics sales. (Items: 2.02 Results of Operations and Financial Condition On November 4, 2026, Innoviva, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits 99)
Tickers: $INVA
Read the full article at SEC EDGAR
Part of the story Crescent Capital BDC Reports Q3 2026 Earnings with Increased Net Investment Income (48 articles)